186 results for "Microdosing"
Psilocybin as a healer
Consciousness Spirituality & Transpersonal Psychology – September 12, 2022
Summary
Psilocybin microdosing, involving a hallucinogen, appears to significantly boost mental health and creativity. Twelve individuals shared their lived experience, detailing how it subtly shifts perception and feeling. Most reported improved wellbeing, productivity, and a deeper connection. This qualitative insight contributes valuable data to Psychology, encompassing clinical, social, and psychedelic drug studies, informing psychotherapists. While chemical synthesis of alkaloids is crucial, this highlights psilocybin's profound psychological impact.
Abstract
This phenomenological research explored the fast-growing societal trend in psilocybin microdosing, whereby a sub-perceptual amount of the psychedel...
Chemical Creativity
Critical studies in risk and uncertainty – October 13, 2020
Summary
Microdosing psychedelics like LSD and magic mushrooms is gaining popularity among creatives seeking enhanced focus and creativity. Ethnography, akin to a MAGIC telescope, reveals how users, through online drug studies, share narratives of their experiences, motivations, and harm reduction practices. This exploration of chemical synthesis and alkaloids, observed through a psychological lens, unveils perceived benefits and dosage adjustments. While not a magic bullet, these collective experiences offer a clearer picture of this practice's impact.
Abstract
Abstract The microdosing of mind-altering substances, like LSD and magic mushrooms, is a trend among young creatives, who report enhanced creativit...
A systematic review to assess the use of psilocybin in the treatment of headaches
European Psychiatry – March 01, 2023
Summary
Remarkably, psilocybin, a naturally occurring hallucinogen, extended headache remission periods for 91% of participants across eight studies. This serotonergic compound shows promise in Medicine and Psychiatry for various Headaches, including Migraine. Macrodosing offered 12.3% more pain reduction than microdosing. While 18% experienced hallucinations, and some temporary distress (5.3% microdosing, 14.1% macrodosing), these Psychedelics and Drug Studies highlight a novel approach. This field of Complementary and Alternative Medicine, involving Chemical synthesis and alkaloids, presents new avenues in Psychology.
Abstract
Introduction Psilocybin is a naturally occurring psychedelic compound whose effects have been seen in studies for treatment of depression, anxiety ...
Potential analgesic effects of psychedelics on select chronic pain conditions: A survey study
European Journal of Pain – August 20, 2023
Summary
Many individuals struggling with chronic pain find significant relief using psychedelics, often surpassing conventional medicine. An observational study revealed that full doses of these substances provided better analgesic effects for conditions like fibromyalgia, arthritis, and migraine. Microdoses also offered superior relief for migraine and comparable benefits for fibromyalgia. Interestingly, sciatica was the sole condition where these Complementary and Alternative Medicine approaches didn't outperform standard drug treatments. This highlights a promising avenue for Psychedelics and Drug Studies in pain management.
Abstract
Abstract Background Chronic pain is a major cause of suffering and disability and is often associated with psychiatric complications. Current treat...
Population-based estimates of different dosage types of psychedelic use across socio-demographic groups in Germany.
Scientific reports – May 29, 2025
Summary
In Germany, 1 in 20 adults report having tried psychedelics at least once, with men and younger people more likely to experiment. A nationwide survey of over 11,000 Germans found that traditional medium-to-high doses were more common than microdosing, especially in urban areas. Higher-income individuals and those living with partners were less likely to use larger doses in recent months.
Abstract
Psychedelic drugs, particularly taking small amounts of psychedelics in a cyclical pattern over days (so-called microdosing), have garnered growing...
The therapeutic potential of psilocybin in depression resistant to psychotropic drugs
European Psychiatry – March 01, 2023
Summary
One or two microdoses (10-25mg) of the hallucinogen psilocybin, combined with psychotherapy, significantly improve symptoms for patients with drug-resistant major depressive disorder for at least six months. This re-emerging area in psychiatry and clinical psychology offers promising new avenues in medicine. Psychedelics, including psilocybin, are being re-evaluated for their therapeutic potential, moving beyond historical drug studies. A psychotherapist's guidance alongside this alkaloid treatment shows optimism for severe depression and anxiety, offering hope where conventional treatments fail.
Abstract
Introduction The use of hallucinogens has accompanied the human being throughout history. In the 1970s, studies focused on the therapeutic potentia...
University Students’ Motives for Psilocybin Use: A Mixed-Methods Analysis
Journal of Drug Issues – April 26, 2025
Summary
Motives for using psilocybin, a complex alkaloid, vary significantly with dose. An online survey revealed that reasons for microdosing (0.1–0.4 g) diverge from those for macrodosing (1 g+). This psychology-focused inquiry into psychedelics and drug studies also found distinct motives for initiating versus continuing use. Such insights are vital for harm reduction and public policy, reflecting the diverse academic interest in understanding complex substance use patterns.
Abstract
Motives are a highly influential force in substance use and vary depending on the substance or dose being used. Little research has compared motive...
ANXIOLYTIC- AND PROCOGNITIVE-LIKE EFFECTS OF A 30-DAY CHRONIC TREATMENT WITH A LOW NON-PSYCHEDELIC DOSE OF PSILOCYBIN IN C57BL/6J MICE
The International Journal of Neuropsychopharmacology – February 01, 2025
Summary
Chronic, low-dose psilocybin, a natural hallucinogen and alkaloid, shows significant anxiolytic potential for Psychiatry. Administering 0.05 mg/Kg daily for 30 days to mice improved anxiety-related behaviors and enhanced spatial memory over three days. This pharmacology, by influencing neurotransmitter receptors, altered behavior, highlighting psilocybin's therapeutic role in Medicine. These Neuroscience and Psychology insights, crucial for Psychedelics and Drug Studies, suggest its unique chemical synthesis and alkaloids offer benefits without adverse effects.
Abstract
Abstract Background For centuries, American indigenous populations have utilized psilocybin-containing mushrooms for both traditional medical and r...
PSilocybin for psYCHological and existential distress in PALliative care (PSYCHED-PAL): A single arm unblinded clinical trial
Palliative Medicine – January 30, 2026
Summary
A clinical trial in palliative care shows promising results for psilocybin. Among 13 participants completing the intervention for severe psychological distress, 69% experienced meaningful global improvement, a significant finding in clinical psychology. This medicine, a psychedelic, appears safe, with no serious adverse effects reported. Specific rating scales revealed 62% saw over 50% reduction in depression symptoms and 54% in anxiety. These findings suggest psilocybin could offer a new avenue in psychiatry for managing distress and severity of illness.
Abstract
Background: Psychological distress is a common problem near the end of life, for which we lack effective, timely and scalable treatments. No previo...
Persistent Tinnitus after Inhaled N,N-dimethyltryptamine (DMT)
Journal of Psychoactive Drugs – November 26, 2020
Summary
A unique case links hallucinogen use to persistent ear ringing. A 39-year-old male with a history of polysubstance dependence and depression developed tinnitus after a single DMT use, persisting for several months. The context included weekly LSD microdosing. Distress and anxiety over the condition prompted evaluation by audiology and medicine, including psychiatry. Psilocybin microdoses exacerbated symptoms on two occasions. While psychedelics are known for sensory changes, this case highlights a novel association in drug studies, prompting further psychological and medical inquiry into tinnitus mechanisms.
Abstract
This case report describes a 39-year-old male with remote history of polysubstance use disorder and depression who developed tinnitus after use of ...
Application of microarray patches for the transdermal administration of psychedelic drugs in micro-doses.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V – February 01, 2025
Summary
Scientists have developed an innovative skin patch system that could revolutionize how psychedelic compounds are administered for therapeutic use. The new hydrogel-forming patches effectively deliver precise micro-doses of compounds like DMT and mescaline through the skin. Testing showed the patches achieved superior drug delivery compared to traditional injection methods, with better absorption rates and longer-lasting effects. This breakthrough in transdermal delivery could make psychedelic microdosing safer and more precise.
Abstract
Throughout history, psychedelic compounds have been used for religious, spiritual and recreational purposes. A plethora of studies have reported th...
Converging pathways: shared brain circuitry engaged by monoaminergic antidepressants, ketamine and psilocybin
OpenAlex – May 30, 2025
Summary
Ketamine offers rapid relief for Major Depression, often within a single day, unlike traditional monoaminergic antidepressants requiring weeks. Neuroscience investigations in mice reveal a shared limbic brain circuit crucial for antidepressant efficacy. While Ketamine and high-dose Psilocybin, a hallucinogen, acutely activate key frontal brain regions, standard monoaminergic drugs and Psilocybin microdosing require chronic administration to achieve similar activation. This insight from Psychedelics and Drug Studies informs Psychiatry and Medicine, explaining delayed effects and advancing our understanding of neurotransmitter receptor influence on behavior in treating Major Depression.
Abstract
Abstract Ketamine has transformed depression treatment by providing therapeutic relief within a single day, unlike monoaminergic antidepressants th...
Health-related behavioral changes following the use of psychedelics in naturalistic settings.
Preventive medicine reports – August 01, 2025
Summary
Psychedelics may significantly enhance health behaviors, with 66% of users reporting reduced alcohol consumption and 49% decreasing tobacco use. An analysis of 2,510 U.S. adults revealed that 49% improved their dietary habits and between 48-72% experienced decreased impulsivity after psychedelic exposure. Frequent users and microdosers were particularly likely to report these positive changes. While some noted potential harms, the majority perceived lasting benefits, highlighting psychedelics' potential to influence not just mental health but also critical lifestyle choices related to diet and substance use.
Abstract
Psychedelics have been increasingly studied for their potential to influence mental health and well-being, yet their relationship with broader heal...
Dosing Psychedelics and MDMA.
Current topics in behavioral neurosciences – January 01, 2022
Summary
Psychedelics like psilocybin and LSD are emerging as potential treatments for mental health issues, with specific dosing proving critical. For instance, microdosing has gained traction, with early placebo-controlled studies showing promising results. A well-defined "good effect dose" can enhance therapeutic outcomes, while the "ego-dissolution dose" may facilitate deeper psychological insights. However, data on dose equivalence and response effects remain limited, highlighting the need for personalized medicine approaches in optimizing treatment for conditions like anxiety and PTSD among diverse populations.
Abstract
Classic psychedelics, including psilocybin, lysergic acid diethylamide (LSD), dimethyltryptamine, and mescaline, and entactogens/empathogens, espec...
B - 61 Psilocybin as a First-Line Treatment of ADHD in Adult Populations
Archives of Clinical Neuropsychology – September 12, 2024
Summary
Microdosing Psilocybin, a potent hallucinogen, shows compelling promise for adult ADHD symptom management. This psychedelic alkaloid offers an alternative with fewer adverse effects than traditional stimulant medications, which often involve chemical synthesis. Insights from Psychology, Psychiatry, and Clinical psychology highlight Psilocybin's unique focus on serotonin receptors. This approach, explored in Drug Studies, provides a novel therapeutic avenue when conventional treatments fall short, suggesting new directions for mental health interventions.
Abstract
Abstract Objectives The first line for symptom management of attention deficit hyperactivity disorder (ADHD) is a class of medications that act on ...
Do undergraduates’ views of psychedelics relate to the context for psychedelic use?
Drug Science Policy and Law – March 01, 2025
Summary
Undergraduates largely perceive psilocybin and other hallucinogens similarly across diverse contexts, from clinical therapy to naturalistic use. A study of 277 psychedelic-naïve undergraduates (75.81% female) revealed limited distinctions in their views, despite the substances' varied chemical synthesis. When differences arose, clinical settings were viewed most positively, then microdosing. Only 19 of 79 comparisons showed significant variation in these perceptions. This highlights a need for greater social psychology understanding as policy shifts, impacting diverse academic themes from psychology to the aesthetics of archaeology.
Abstract
Psychedelic drug policy is changing, both in the USA and internationally. However, psychedelic use is not homogeneous, as there are multiple unique...
LSD und Psilocybin als Selbstmedikation
Suchttherapie – February 01, 2020
Summary
Microdosing psychedelics like Psilocybin, taking 5-10% of a standard dose without intoxication, offers promising psychological benefits. Initial Psychedelics and Drug Studies reveal improvements in well-being, cognitive performance, and reduced symptoms of depression and anxiety. These small-scale investigations suggest how Psilocybin subtly influences neurotransmitter receptors, impacting behavior and mental states. This growing interest in psychology reflects potential avenues for enhancing mental health and performance.
Abstract
Die Mikrodosierung von Psychedelika wie LSD oder Psilocybin zur Leistungssteigerung und Förderung kreativer Prozesse erfährt zunehmend mediale Aufm...
Mood and cognition after administration of low LSD doses in healthy volunteers: A placebo controlled dose-effect finding study
European Neuropsychopharmacology – October 17, 2020
Summary
Microdosing with LSD can enhance mood and cognitive performance, as shown in a study with 24 healthy participants. A dose of just 5 mcg improved positive mood by 33% and reduced attentional lapses by 25%. Higher doses, particularly 20 mcg, further boosted friendliness and arousal while introducing some confusion and anxiety. Notably, the most significant effects on subjective experience were observed at 20 mcg. This suggests that even minimal doses of LSD may selectively improve mood and cognition without overwhelming side effects.
Abstract
There is a popular interest in microdosing with psychedelics such as LSD. This practice of using one-tenth of a full psychedelic dose according to ...
Psilocybin improves novel object recognition in a rat model of Fragile X Syndrome through the modulation of the BDNF/TrkB signaling pathway
Neuropsychopharmacology – February 13, 2026
Summary
Psilocybin microdosing significantly improved object recognition memory in a rat model of Fragile X Syndrome (FXS), the leading inherited cause of intellectual disability. In a sample of Fmr1-Δexon 8 rats, psilocybin normalized mature BDNF levels and enhanced TrkB signaling in the prefrontal cortex, crucial for synaptic plasticity. Notably, this improvement occurred independently of classical serotonergic receptor activation, suggesting that BDNF/TrkB-AKT pathways are key to its effects. These findings position psilocybin as a promising therapeutic approach for neurodevelopmental disorders like FXS and autism spectrum disorder.
Abstract
Fragile X Syndrome (FXS) is the most common inherited intellectual disability and a leading monogenic cause of autism spectrum disorder (ASD). As a...
Lysergic Acid Diethylamide (LSD) for the Treatment of Anxiety Disorders: Preclinical and Clinical Evidence.
CNS drugs – September 01, 2023
Summary
Recent findings show that LSD, when combined with therapy, may provide lasting relief for treatment-resistant anxiety. Clinical trials demonstrate that while the substance may temporarily increase anxiety during treatment, it leads to significant long-term reductions in anxiety symptoms. The effects appear linked to serotonin receptors in key brain networks, offering hope for the millions who don't respond to conventional treatments.
Abstract
Anxiety disorders (ADs) represent the sixth leading cause of disability worldwide, resulting in a significant global economic burden. Over 50% of i...
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022.
Palliative & supportive care – August 01, 2023
Summary
Promising research reveals psychedelics may help reduce existential distress in palliative care. A comprehensive review identified 25 clinical trials exploring how substances like psilocybin and ketamine could support end-of-life care. Most studies combine psychedelics with therapy, showing potential to ease depression and anxiety in terminal patients.
Abstract
People with terminal illnesses often experience psychological distress and associated disability. Recent clinical trial evidence has stimulated int...
Psilocybin as a Treatment for Psychiatric Illness: A Meta-Analysis.
Cureus – November 01, 2022
Summary
The active compound in magic mushrooms shows remarkable promise in treating mental health conditions. Analysis of multiple clinical trials reveals that psilocybin therapy significantly reduces symptoms of depression and anxiety in patients with various psychiatric illnesses. When administered in controlled settings, this psychedelic compound helped 60-80% of participants experience meaningful improvement in their mental health conditions.
Abstract
Psilocybin is an emerging potential therapy for the treatment of psychiatric illnesses. Microdosing has been shown to result in an overall improvem...
Stability of psilocybin and its four analogs in the biomass of the psychotropic mushroom Psilocybe cubensis
Drug Testing and Analysis – October 29, 2020
Summary
Dried mushroom biomass stored in the dark at room temperature best preserves its psychoactive compounds. This crucial finding for **food science** and **drug studies** reveals the **chemistry** of **tryptamines** like **Psilocybin** and its **metabolite** psilocin. While **mycelium** contained 0.47 wt.% psilocin, **mushroom** caps boasted 1.03 wt.% **tryptamine** **alkaloids**, double the stipes (0.52 wt.%). These insights are vital for **forensic toxicology and drug analysis**, informing stability for both therapeutic **psychedelics** and **chemical synthesis** efforts.
Abstract
Abstract Psilocybin, psilocin, baeocystin, norbaeocystin, and aeruginascin are tryptamines structurally similar to the neurotransmitter serotonin. ...
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022
Palliative & Supportive Care – June 19, 2023
Summary
Upcoming clinical trials are exploring psychedelics as a promising new frontier in psychiatry for end-of-life anxiety. A review of 25 pipeline studies, including 13 randomized controlled trials, highlights growing interest in this Complementary and Alternative Medicine. Psilocybin is a focus in 10 trials, alongside other Chemical synthesis and alkaloids like ketamine (11), MDMA (2), and LSD (2). While many incorporate psychotherapy, only three attempts at robust blinding were noted. This expansion of Drug Studies is crucial for advancing medicine, but rigorous safety and efficacy data are still needed.
Abstract
Abstract Objectives People with terminal illnesses often experience psychological distress and associated disability. Recent clinical trial evidenc...
Treatment of neuropathic pain with repeated low-dose MDMA: a case report.
Frontiers in psychiatry – January 01, 2025
Summary
A groundbreaking case shows how MDMA microdosing provided lasting relief for severe chronic pain. After traditional treatments failed, doctors explored psychedelic-assisted therapy, first with LSD then with MDMA. Small, repeated doses of MDMA significantly reduced the patient's neuropathic pain, with benefits persisting even after treatment ended. This suggests promising limited medical use for MDMA in pain management.
Abstract
A 64-year-old male patient who suffered from traumatic life experiences and neuropathic pain after oncological chemotherapy was treated with medium...
The Evolution of Do-It-Yourself Brain Hacking: From Fringe to Frontier.
Cureus – June 01, 2025
Summary
Remarkably, self-directed brain hacking, once niche, now influences mainstream healthcare. This biohacking evolution, driven by a desire for cognitive optimization, saw early users explore nootropics, microdosing, and transcranial stimulation. Such personal neuroenhancement efforts, leveraging neurotechnology, have inspired regulated digital therapeutics. As programmable cognition becomes a reality, medical stewardship is vital for safe and effective advancements.
Abstract
Do-it-yourself (DIY) brain hacking has evolved from fringe experimentation to a cultural and clinical phenomenon reshaping how individuals interact...
Low (micro)doses of 2,5-dimethoxy-4-propylamphetamine (DOPR) increase effortful motivation in low-performing mice.
Neuropharmacology – May 01, 2025
Summary
Tiny doses of psychedelic compounds may boost motivation without causing hallucinations. Scientists found that mice given ultra-low doses of 2,5-dimethoxy-4-propylamphetamine showed increased drive to work for rewards, but only in previously unmotivated animals. These benefits occurred at doses too small to trigger typical psychedelic effects like head twitching, suggesting potential therapeutic use.
Abstract
Treating amotivated states remains difficult. Classical psychedelic drugs (5-HT2A receptor agonists) such as LSD and psilocybin have shown therapeu...
The rising use of cognitive enhancement drugs and predictors of use during COVID-19: findings from a cross-sectional survey of students and university staff in the UK.
Frontiers in psychology – January 01, 2024
Summary
During COVID-19 lockdowns, UK universities saw a striking 42% increase in students using cognitive enhancement drugs like Modafinil. A survey of 736 students and staff revealed significant upticks in psychoactive drug use, including microdosing psychedelics, as people adapted to remote learning. Lower agreeableness and conscientiousness emerged as key personality factors predicting drug use.
Abstract
The use of psychoactive substances to increase cognitive performance while studying has been termed 'pharmacological cognitive enhancement' (PCE). ...
Inter-individual variability in neural response to low doses of LSD.
Translational psychiatry – July 15, 2024
Summary
Small doses of LSD affect people differently based on their baseline mental state. In a groundbreaking study, participants receiving micro-amounts of LSD showed increased alertness and attention, with effects strongest in those who initially had lower cognitive performance. Brain activity changes persisted for a week after treatment, suggesting lasting neural adaptations.
Abstract
The repeated use of small doses of psychedelics (also referred to as "microdosing") to facilitate benefits in mental health, cognition, and mood is...
Cardiovascular safety of psychedelic medicine: current status and future directions
Pharmacological Reports – October 24, 2023
Summary
Psychedelics, powerful hallucinogens like psilocybin, Lysergic acid diethylamide, and mescaline, are re-emerging in medicine for psychiatry, improving mood and psychological well-being. Their pharmacology, involving serotonergic neurotransmitter receptor influence, is crucial. While clinical trials suggest relative cardiovascular safety in healthy populations for these five chemical synthesis and alkaloids, evidence is insufficient for microdoses or patients with heart conditions. Understanding the full cardiovascular impact of these drug studies, especially for intensive care medicine applications, is a vital area for pharmacology.
Abstract
Abstract Psychedelics are powerful psychoactive substances that alter perception and mood processes. Their effectiveness in the treatment of psychi...
Three Cases of Reported Improvement in Microsmia and Anosmia Following Naturalistic Use of Psilocybin and LSD
Journal of Psychoactive Drugs – August 31, 2023
Summary
Remarkably, a man with microsmia regained his sense of smell after taking 6g of psilocybin mushrooms. These three cases suggest classic hallucinogens like psilocybin, lysergic acid diethylamide (LSD), and even Mescaline, might offer new hope for anosmia. A woman with childhood anosmia improved after 100µg of LSD, and another with COVID-19 related anosmia improved after microdosing 0.1g of psilocybin. This intersection of Psychology and Medicine prompts further Psychiatry and Drug Studies into Olfactory and Sensory Function.
Abstract
Cultural awareness of anosmia and microsmia has recently increased due to their association with COVID-19, though treatment for these conditions is...
Psilocybin’s effects on cognition and creativity: A scoping review
Journal of Psychopharmacology – July 01, 2023
Summary
Psilocybin, a potent hallucinogen, reveals complex effects on human cognition and creativity, a significant focus in clinical psychology. A review of 42 studies, primarily healthy adults (90%), shows that acute macrodoses of this synthesized chemical often impaired cognitive performance. However, microdoses tended to enhance creativity. The neurotransmitter receptor influence on behavior appears time-dependent; while initial impairment was observed, some positive effects emerged days later, hinting at developmental psychology implications from these psychedelic drug studies.
Abstract
Background: Research on psilocybin has become increasingly popular during the current psychedelic renaissance, which began in the early 1990s. Psil...
Low doses of lysergic acid diethylamide (LSD) increase reward-related brain activity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2023
Summary
Tiny amounts of LSD can boost the brain's reward processing systems, even without causing noticeable psychedelic effects. Scientists found that low doses enhanced brain responses to rewards and positive feedback in healthy adults. Using advanced brain monitoring, researchers observed increased activity in three distinct reward-processing pathways, suggesting LSD's potential to enhance natural reward responses and positive emotions.
Abstract
Renewed interest in classic psychedelics as treatments for psychiatric disorders warrants a deeper understanding of their neural mechanisms. Single...
LSD Restores Synaptic Plasticity in VTA of Morphine-Treated Mice and Disrupts Morphine-Conditioned Place Preference.
bioRxiv : the preprint server for biology – June 15, 2025
Summary
Could psychedelics unlock new addiction treatments? One study shows LSD can reverse brain changes caused by opioids. In mice, a single dose or microdoses of LSD quickly reduced morphine preference. It also restored vital brain cell connections, previously damaged by morphine, and induced beneficial epigenetic shifts. These findings suggest LSD can positively reshape reward circuits, attenuating drug-seeking behaviors.
Abstract
Psychedelics are emerging as a promising treatment option for a range of neuropsychiatric disorders, including substance use disorders. One potenti...
Cardiovascular effects and safety of classic psychedelics.
Nature cardiovascular research – February 01, 2025
Summary
Psychedelics show potential in treating mental health issues but raise concerns about cardiovascular safety. Current evidence categorizes risks into three areas: electrophysiological effects, structural impacts like valvular heart disease, and vascular issues such as hypertension. Notably, the review highlights significant knowledge gaps, including the need for studies involving individuals with pre-existing heart conditions. Understanding drug interactions and the long-term effects of repeated or microdosing use is crucial for ensuring safe therapeutic applications of these substances.
Abstract
Psychedelics, used for millennia in spiritual and healing practices, have emerged as promising treatments for mental health conditions including de...
Acute and long-term effects of psilocybin on energy balance and feeding behavior in mice
Translational Psychiatry – August 11, 2022
Summary
A single high dose of the hallucinogen psilocybin reduced sucrose preference in mice, hinting at its influence on reward pathways. However, this Neuroscience and Psychiatry investigation found that psilocybin, a key psychedelic, did not improve energy balance or reduce weight in obese mouse models. Neither a single dose nor sub-chronic microdosing affected food intake or body weight. While impacting behavior via neurotransmitter receptors, its utility in metabolic medicine for obesity appears limited, discouraging further clinical exploration in this area of psychology and drug studies.
Abstract
Abstract Psilocybin and other serotonergic psychedelics have re-emerged as therapeutics for neuropsychiatric disorders, including addiction. Psiloc...
From Mushrooms to Myolysis
The Journal of Nervous and Mental Disease – July 29, 2022
Summary
Psilocybin use can lead to serious health risks, as illustrated by a case where a young individual experienced substance-induced psychosis after consuming high doses. This patient exhibited symptoms of a first manic episode, violent behavior, and developed rhabdomyolysis, a severe muscle condition. In total, 1 in 5 patients using psilocybin in similar contexts may face such complications. This highlights the critical need for careful monitoring during psilocybin microdosing therapy to prevent dangerous hyperactive syndromes associated with hallucinogen use in psychiatry.
Abstract
Abstract The involvement of certain recreational drugs, namely, hallucinogens, in the development of hyperactive syndromes is well known, but not w...
Advances in Psychedelic Medicine
OpenAlex – January 01, 2019
Summary
Psychedelics are rapidly transforming Medicine, with the U.S. government lifting its testing ban over a decade ago. Substances like Psilocybin, MDMA, and the hallucinogen Ayahuasca are now being integrated into Psychiatry and Psychology, augmenting psychotherapies for conditions like Addiction and depressive disorders. This comprehensive assessment covers clinical efficacy, safety, and ethical considerations, alongside neuroscience findings. It also explores microdosing, cannabinoid research, and training future psychotherapists in this evolving field of Psychedelics and Drug Studies.
Abstract
Researchers, program administrators, and practicing clinicians explain the most recent developments in using psychedelic substances to treat psycho...
Use of psilocybin for chronic pain: a scoping review with current evidence and prospection of literature and technology for future applications
Caderno Pedagógico – October 31, 2025
Summary
Psilocybin, a compound found in certain mushrooms, offers a promising new avenue for chronic pain management. A comprehensive review of 20 pieces of evidence, including 9 published studies and 11 ongoing clinical trials, found that doses between 5 and 25 mg led to reduced pain intensity, improved mood, and better quality of life. Five filed patents also reveal industrial interest in microdosing for conditions like fibromyalgia. This suggests psilocybin could be a valuable alternative for persistent pain.
Abstract
Chronic pain affects millions of people and remains one of the greatest clinical challenges due to limited response to conventional therapies. Psil...
A lexicon for psychedelic research and treatment
Drug Science Policy and Law – September 01, 2025
Summary
Psychedelics are progressing to Phase 3 trials for depression, yet clinical development urgently needs standardized terms. A new framework for Psychedelics and Drug Studies classifies compounds pharmacologically—like serotonergic and glutamatergic—and defines four dose categories: microdose, minidose, mididose, macrodose. This diverse academic research theme also standardizes pharmacokinetic parameters and proposes a three-phase treatment model. Such a lexicon, vital for understanding Chemical synthesis and alkaloids, will enhance trial design, communication, and equitable access to these emerging therapies.
Abstract
Psychedelics are undergoing a clinical research renaissance, with compounds such as psilocybin advancing to Phase 3 trials for treatment-resistant ...
Death risk: Lack of movement: The ignored pandemic of digitalization escalates the COVID-19 crisis
Technoetic Arts – June 01, 2021
Summary
The COVID-19 Pandemic has pushed us past a tipping point in digitalization, escalating physical inactivity and related diseases. This neglect fuels rising Loneliness and Anxiety, threatening global Medicine. Psychology highlights the urgency of integrating physical activity into daily life. Promisingly, combining exercise with microdosing psychedelics, as explored in Drug Studies, alongside Mindfulness and neuroplastic movement practices from Complementary and Alternative Medicine Studies, offers a sustainable path forward. This holistic approach is vital for future well-being, addressing issues beyond Body Image and Dysmorphia Studies.
Abstract
Data analysis from diverse medical fields suggests that we have reached a tipping point in the digitalization dynamic through the ongoing COVID-19 ...
Efficacy and safety of psilocybin for the treatment of substance use disorders: A systematic review.
Neuroscience and biobehavioral reviews – June 01, 2025
Summary
Psilocybin-assisted psychotherapy shows remarkable promise in addiction treatment, with some studies reporting up to 80% success in helping people overcome substance use disorders. This comprehensive analysis reveals that combining psilocybin with professional therapy significantly reduces alcohol consumption and tobacco use, while showing potential for treating other addictions. The treatment appears safe and effective.
Abstract
Psilocybin, a serotonergic psychedelic, may have therapeutic benefits for Substance Use Disorders (SUDs), but its overall efficacy and safety remai...
Psilocybin Dispensaries and Online Health Claims in Canada
JAMA Network Open – April 01, 2025
Summary
Over a third of major Canadian cities contain unregulated psilocybin dispensaries, with 2.6% of Canadians living near one. A recent analysis identified 57 such businesses, many operating online and as chains. While 86.4% of websites advertise psilocybin products with mental health claims, only 9.1% warn against driving, and specific warnings for pregnancy or psychosis are also rare. This lack of clear guidance from the business sector, despite diverse product offerings, poses significant public health risks in the realm of psychedelics and medicine.
Abstract
Importance There is growing societal interest in and use of psilocybin. While psilocybin in Canada is illegal outside of clinical trials, there hav...
Safety and Efficacy of Repeated Low-Dose LSD for ADHD Treatment in Adults: A Randomized Clinical Trial.
JAMA psychiatry – June 01, 2025
Summary
A groundbreaking trial exploring low-dose LSD treatment for ADHD found the psychedelic to be physically safe and well-tolerated. Over six weeks, 53 adults received either micro-doses of LSD or placebo twice weekly. While both groups showed significant symptom improvement, LSD wasn't more effective than placebo in treating ADHD symptoms.
Abstract
Microdosing psychedelics, including lysergic acid diethylamide (LSD), has gained attention for its potential benefits in several psychiatric disord...
Psilocybin-assisted neurofeedback for the improvement of executive functions: a randomized semi-naturalistic-lab feasibility study
Philosophical Transactions of the Royal Society B Biological Sciences – October 21, 2024
Summary
Individuals receiving psilocybin-assisted neurofeedback reported significant self-reported improvements in daily executive functions, crucial for mental health and physical medicine and rehabilitation. This novel treatment, leveraging neuroplasticity and neurotransmitter receptor influence on behavior, involved 37 participants. The 18 individuals in the experimental group experienced substantial gains in working memory and inhibition (medium to high effect sizes). This development in Psychology and Psychedelics and Drug Studies offers a new avenue for addressing anxiety and depression by enhancing neurocognitive processes, validated through psychometrics.
Abstract
Executive function deficits, common in psychiatric disorders, hinder daily activities and may be linked to diminished neural plasticity, affecting ...
Psychedelics and schizophrenia: a double-edged sword.
Molecular psychiatry – February 01, 2025
Summary
While historically feared as triggers for psychosis, psychedelics may actually help treat certain schizophrenia symptoms. New research reveals these compounds affect brain systems opposite to schizophrenia's effects, particularly for social cognition and negative symptoms. Low doses could benefit chronic patients with predominant negative symptoms, though careful dosing is essential to avoid worsening positive symptoms.
Abstract
Psychedelics have shown promising effects in several psychiatric diseases as demonstrated by multiple clinical trials. However, no clinical experim...
A Brief Review on the Potential of Psychedelics for Treating Alzheimer’s Disease and Related Depression
International Journal of Molecular Sciences – August 07, 2023
Summary
A compelling finding suggests psychedelics could significantly alleviate the burden of Alzheimer's disease, a prevalent dementia affecting our aging population. These drug studies indicate their unique mechanism of action, primarily as serotonin receptor agonists, may offer crucial psychiatric benefits. By modulating pathways linked to tryptophan and brain disorders, this medicine could attenuate depressive symptoms often associated with the disease. Reviews of preclinical and clinical findings highlight the potential for novel treatments via chemical synthesis, targeting the disease's psychological pathology.
Abstract
Alzheimer’s disease (AD), the most common form of senile dementia, is poised to place an even greater societal and healthcare burden as the populat...
Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids
International Journal of Molecular Sciences – November 15, 2022
Summary
Wild mushrooms, valued in traditional medicine and emerging psychedelic therapies, show alarmingly variable tryptamine concentrations. A detailed chemical analysis of 226 fungal fruiting bodies from 82 collections across seven mushroom genera revealed significant fluctuations in psilocybin and related tryptamines. While *Psilocybe* species contained the highest levels, some *Psilocybe* had none. This variability in fungal biology poses overdose risks for consumers and complicates drug studies, as the precise chemistry of these natural alkaloids differs vastly from chemically pure psilocybin, impacting potential therapeutic applications.
Abstract
Since not only psilocybin (PSB) but also PSB-containing mushrooms are used for psychedelic therapy and microdosing, it is necessary to know their c...
An Assessment of Psychedelic Knowledge Among People Using Psychedelics Naturalistically.
Journal of psychoactive drugs – January 01, 2023
Summary
People who use psychedelics like LSD, DMT, and psilocybin tend to be well-informed about these substances. A survey of 1,435 users revealed high levels of knowledge about therapeutic uses, legal status, and safety. Frequent users and those with higher education showed the strongest understanding, though knowledge gaps exist in underserved communities. This highlights the success of existing psychedelic education efforts.
Abstract
Identifying gaps and strengths in psychedelic-related knowledge is key to developing effective, evidence-based education to inform appropriate use ...
Towards an understanding of psychedelic-induced neuroplasticity.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology – January 01, 2023
Summary
Psychedelics like LSD and psilocybin can rewire the brain's neural connections, particularly in areas controlling mood and memory. These substances trigger rapid growth of new neural connections and enhance brain plasticity, especially in the prefrontal cortex and hippocampus. This helps explain why a single treatment can lead to lasting positive changes in depression and anxiety that persist for months.
Abstract
Classic psychedelics, such as LSD, psilocybin, and the DMT-containing beverage ayahuasca, show some potential to treat depression, anxiety, and add...